UBT251 is a once-weekly triple-agonist peptide that activates GLP-1, GIP and glucagon. In Phase 2, its best-performing dose group averaged 19.7% weight loss in just 24 weeks.
That is why the “triple agonist” story is no longer only about retatrutide. UBT251 targets the same three receptor families with a different peptide, and a larger global study is now testing whether its early result travels well.
The 20-second answer
See current retatrutide research specifications →
Why is UBT251 getting so much attention?
Because 19.7% in 24 weeks is a number people notice. It came from a Phase 2 study of 205 adults with obesity in China. Participants received UBT251 or a placebo once a week.
The result also matters because UBT251 is only the second high-profile peptide to make the three-target idea feel real. Instead of pressing one metabolic button, it presses three:
- GLP-1 helps reduce appetite and supports blood-sugar control.
- GIP works with nutrient and insulin signals.
- Glucagon can raise energy use and affects how the liver handles fuel.
The goal is not simply “more receptors.” The goal is to make the three signals work together in the right balance.
What did the UBT251 Phase 2 study show?
The study tested several weekly doses for 24 weeks. Average weight loss rose as the dose increased, although the highest dose did not produce the best number.
| Weekly group | Average weight loss at 24 weeks |
|---|---|
| 2 mg | 13.6% |
| 4 mg, lower starting dose | 16.2% |
| 4 mg, higher starting dose | 19.7% |
| 6 mg | 18.7% |
| Placebo | 2.0% |
The most interesting detail is the 4 mg group, not the 6 mg group, produced the largest average change. That is a useful reminder that dose design is about finding the sweet spot, not simply using the biggest number.
Stomach-related side effects were the most common, as they are with many incretin medicines. The global study can help show which starting dose and step-up schedule are easiest for people to stay with.
UBT251 vs retatrutide: same targets, different peptides
UBT251 and retatrutide both activate GLP-1, GIP and glucagon receptors. That makes retatrutide the most useful research comparison, but the molecules are not copies.
| UBT251 | Retatrutide | |
|---|---|---|
| Targets | GLP-1 + GIP + glucagon | GLP-1 + GIP + glucagon |
| Format | Long-acting peptide | Long-acting peptide |
| Current development | Phase 2 | Phase 3 |
| Best-known headline | 19.7% at 24 weeks | 24.2% at 48 weeks in Phase 2 |
Those numbers come from separate trials with different people, doses and study lengths, so they are a watchlist—not a head-to-head scoreboard. The exciting part is that researchers now have two different triple-agonist designs to follow.
Read our retatrutide Phase 3 update or see retatrutide vs tirzepatide for a simple explanation of how three targets differ from two.
What is the global UBT251 trial?
Novo Nordisk is sponsoring a Phase 2 study outside China. It plans to enroll about 333 adults with overweight or obesity and study weekly injections through 2027.
This is the next important test. A regional result can start a conversation; a larger global program can show whether the dose-response pattern holds across a broader mix of people.
The program also has an unusual business story. United Biotechnology developed UBT251 and kept rights in China, Hong Kong, Macau and Taiwan. Novo Nordisk holds development rights in the rest of the world. That partnership gives the peptide both local experience and global clinical reach.
Why UBT251 matters to research buyers
UBT251 makes multi-receptor peptide identity more important, not less. Two products can both be called “triple agonists” while having different sequences, potency and purity profiles.
For any metabolic research peptide, ask for:
- the exact compound name and sequence or specification;
- a current, batch-specific certificate of analysis;
- HPLC purity data and mass-spectrometry identity data;
- current stock, pack size, lead time and storage information.
Certiva currently offers documented research materials including retatrutide, tirzepatide and semaglutide. Our guide to HPLC vs mass spectrometry explains why buyers should ask for both types of evidence instead of accepting one purity number.
Why UBT251 is a three-signal candidate
UBT251 is easy to remember: three receptor targets and up to 19.7% average weight loss in 24 weeks. Its early data make it a serious peptide to watch, and the global Phase 2 study will show whether that result can hold up on a wider stage.
For research purchasing today, the best comparison is a documented triple-agonist material with a current batch COA—not a product name alone.
Request current retatrutide COAs and pricing →
UBT251 remains investigational and is not approved for personal use. Certiva products are supplied for laboratory research only, not for human use.
Frequently asked questions
What is UBT251?
UBT251 is a weekly research peptide that activates GLP-1, GIP and glucagon. Its best-performing Phase 2 dose group averaged 19.7% weight loss in 24 weeks.
How much weight did people lose with UBT251?
The best-performing group in a 205-person Phase 2 study averaged 19.7% weight loss after 24 weeks, compared with 2.0% for placebo.
Why is UBT251 called a triple agonist?
It is called a triple agonist because one peptide activates three receptor pathways—GLP-1, GIP and glucagon—at the same time.
Is UBT251 the same as retatrutide?
No. UBT251 and retatrutide target the same three receptor families, but they are different peptide molecules from different development programs.
Is there a global UBT251 study?
Yes. A global Phase 2 study is testing weekly UBT251 in about 333 adults with overweight or obesity, with study activity planned through 2027.
Is UBT251 approved?
No. UBT251 is an investigational peptide in Phase 2 development. It is not currently approved for sale or personal use.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →